Takeda Pharmaceutical (TAK) Free Cash Flow (QoQ) (2018 - 2026)
Takeda Pharmaceutical (TAK) Free Cash Flow (QoQ) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.83 Bn | 32.09 Bn | 1.97 Bn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -113.85% |
| Dec 31, 2025 | -5.04% |
| Sep 30, 2025 | 56.00% |
| Jun 30, 2025 | 312.54% |
| Mar 31, 2025 | -130.36% |
| Dec 31, 2024 | 27.34% |
| Sep 30, 2024 | 51.42% |
| Jun 30, 2024 | 882.27% |
| Mar 31, 2024 | -114.28% |
| Dec 31, 2023 | -20.14% |
| Sep 30, 2023 | 62.38% |
| Jun 30, 2023 | 177.36% |
| Mar 31, 2023 | -87.51% |
| Dec 31, 2022 | 60.80% |
| Sep 30, 2022 | 85.47% |
| Jun 30, 2022 | -31.04% |
| Mar 31, 2022 | -57.00% |
| Dec 31, 2021 | 37.45% |
| Sep 30, 2021 | 33.43% |
| Jun 30, 2021 | -11.42% |